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The indication for pulmonary artery banding
is currently limited by several factors:
a) the difficulty of determining the optimal band
perimeter, since minor changes in diameter
have a major impact on blood flow and pressure
gradient across the band site;
b) the influence of several mutually interfering
clinical variables, including general anaesthesia
with positive pressure ventilation, chest open-
ing (particularly by thoracotomy), heart rate
and contractility, arterial PO2 and PCO2, acid-
base status, haematocrit [1];
c) variability of ventricular adaptive response, par-
ticularly in “functionally” univentricular hearts
[2], transposition of the great arteries requiring
left ventricular retraining for arterial switch
operation [3], and with associated procedures;
d) repeated surgery frequently required adjust-
ment of the band or long periods of intensive
respiratory/pharmacological intervention to
control pulmonary blood flow [3].
Several attempts have failed to produce ad-
justable pulmonary artery banding with reliable
external regulation: MedLine research revealed 
16 different techniques over the last 10 years.
An implantable, telemetrically controlled,
battery-free device (FloWatch™), developed by
EndoArt SA, a medical company established in
Lausanne, Switzerland, for externally adjustable
pulmonary artery banding [4], was evaluated on
mini-pigs and proved to be effective for up to 
6 months [5].
The FloWatch™ system comprises implant
and external control unit. The change in the 
adjustable area is obtained by a piston driven by an
incorporated electrical micro-motor. The adjust-
ment is done via the external control unit, deliver-
ing energy as well as commands to drive the micro-
engine [4]. 
After completion of our experimental study
[5], and with the approval of the Institutional Eth-
ical Committee, the first human implant was per-
formed in a girl with Down’s syndrome, complete
atrioventricular septal defect with unbalanced
ventricles, large patent ductus arteriosus and
pulmonary hypertension. At one month of age she
underwent closure of the patent ductus arteriosus
The indication for pulmonary artery banding
is currently limited by several factors. Previous
attempts have failed to produce adjustable pul-
monary artery banding with reliable external reg-
ulation. An implantable, telemetrically controlled,
battery-free device (FloWatch™) developed by
EndoArt SA, a medical company established in
Lausanne, Switzerland, for externally adjustable
pulmonary artery banding was evaluated on mini-
pigs and proved to be effective for up to 6 months.
The first human implant was performed on a girl
with complete atrioventricular septal defect with
unbalanced ventricles, large patent ductus arterio-
sus and pulmonary hypertension. At one month of
age she underwent closure of the patent ductus
arteriosus and FloWatch™ implantation around
the pulmonary artery through conventional left
thoracotomy. The surgical procedure was rapid
and uneventful. During the entire postoperative
period bedside adjustments (narrowing or release
of pulmonary artery banding with echocardio-
graphic assessment) were repeatedly required to
maintain an adequate pressure gradient. The early
clinical results demonstrated the clinical benefits
of unlimited external telemetric adjustments. The
next step will be a multi-centre clinical trial to con-
firm the early results and adapt therapeutic strate-
gies to this promising technology.
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and FloWatch™ implantation around the pul-
monary artery through conventional left thoraco-
tomy. The surgical procedure was rapid and un-
eventful. During the entire postoperative period
(fig. 1) bedside adjustments (narrowing or release
of pulmonary artery banding with echocardio-
graphic assessment) were repeatedly required to
maintain an adequate pressure gradient.
Several literature reports have confirmed the
clinical need for externally adjustable pulmonary
artery banding. Our experimental research [5] has
tested a device (FloWatch™) for telemetrically
adjustable pulmonary artery banding very easy to
implant and use. The early clinical results have
demonstrated the clinical benefits of unlimited
external telemetric adjustments. The next step will
be a multi-centre clinical trial to confirm the early
results and adapt therapeutic strategies to this
promising technology.
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Figure 1
Postoperative chest
X-ray showing the
FloWatch™ im-
planted around the
pulmonary artery.
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